GlucoTrack unit Lokahi Therapeutics expands ai2 Futures Lab collaboration with University of Georgia

• GlucoTrack’s Lōkahi Therapeutics renewed the University of Georgia’s participation in its ai² Futures Lab asset-origination program.
• Program aims to expand sourcing of therapeutic acquisition candidates viewed as overlooked or deprioritized, supporting pipeline build-out.
• In its first year, the lab engaged 64 students, identifying more than 45 potential acquisition assets; several moved into active discussions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260821440277) on August 21, 2026, and is solely responsible for the information contained therein.